Myocardial Fatty Acid Metabolism and Lipotoxicity in the Setting of Insulin Resistance

Heart Failure Clinics

Volumn 8, Issue 4, 2012, Pages 643-661

  Kok, Bernard P C ^a   Brindley, David N ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Cardiomyopathy; Cardiovascular disease; Diabetes; Fatty acid oxidation; Lipid accumulation; Metabolic inflexibility

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADENOSINE TRIPHOSPHATE; APOLIPOPROTEIN B48; CARNITINE PALMITOYLTRANSFERASE I; CHYLOMICRON; CYCLIC AMP DEPENDENT PROTEIN KINASE; ETOMOXIR; EZETIMIBE; FATTY ACID BINDING PROTEIN; FIBRIC ACID DERIVATIVE; GLYCEROL 3 PHOSPHATE ACYLTRANSFERASE; GLYCEROLIPID; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOXAZOLINE DERIVATIVE; LIPOPROTEIN RECEPTOR; MALONYL COENZYME A DECARBOXYLASE; METFORMIN; NICOTINIC ACID; OXFENICINE; RANOLAZINE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRIMETAZIDINE; VERY LOW DENSITY LIPOPROTEIN;

ABDOMINAL OBESITY; CARDIOVASCULAR RISK; COMORBIDITY; DIABETIC CARDIOMYOPATHY; DYSLIPIDEMIA; FATTY ACID METABOLISM; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; GLYCOLYSIS; HEART FAILURE; HEART MUSCLE CELL; HEART MUSCLE METABOLISM; HUMAN; HYPERTENSION; IMMOBILIZATION; INCIDENCE; INSULIN RESISTANCE; LIFE EXPECTANCY; LIPID HYDROLYSIS; LIPID STORAGE; LIPOLYSIS; LIPOTOXICITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PHENOTYPE; PREVALENCE; RADIOENZYMATIC ASSAY; RESPIRATORY CHAIN; REVIEW; SMOKING;

CARDIOVASCULAR DISEASES; DIABETIC CARDIOMYOPATHIES; ENDOPLASMIC RETICULUM; FATTY ACIDS; HUMANS; HYPERGLYCEMIA; HYPERLIPIDEMIAS; INSULIN RESISTANCE; MITOCHONDRIA; MYOCARDIUM; MYOCYTES, CARDIAC; OXIDATIVE STRESS; RISK FACTORS;

EID: 84866612006     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2012.06.008     Document Type: Review

References (235)

1. Cornier M.A., Dabelea D., Hernandez T.L., et al. The metabolic syndrome. Endocr Rev 2008, 29(7):777-822.
2. Moller D.E., Kaufman K.D. Metabolic syndrome: a clinical and molecular perspective. Annu Rev Med 2005, 56:45-62.
3. Ford E.S., Ajani U.A., Croft J.B., et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med 2007, 356(23):2388-2398.
4. Brophy J.M. The epidemiology of acute myocardial infarction and ischemic heart disease in Canada: data from 1976 to 1991. Can J Cardiol 1997, 13(5):474-478.
5. Shaw J.E., Sicree R.A., Zimmet P.Z. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010, 87(1):4-14.
6. Freund K.M., Belanger A.J., D'Agostino R.B., et al. The health risks of smoking. The Framingham Study: 34 years of follow-up. Ann Epidemiol 1993, 3(4):417-424.
7. Stokes J., Kannel W.B., Wolf P.A., et al. Blood pressure as a risk factor for cardiovascular disease. The Framingham Study-30 years of follow-up. Hypertension 1989, 13(Suppl 5):I13-I18.
8. Turner R.C., Millns H., Neil H.A., et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998, 316(7134):823-828.
9. Manninen V., Tenkanen L., Koskinen P., et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992, 85(1):37-45.
10. Manttari M., Huttunen J.K., Koskinen P., et al. Lipoproteins and coronary heart disease in the Helsinki Heart Study. Eur Heart J 1990, 11(Suppl H):26-31.
11. Tenkanen L., Pietila K., Manninen V., et al. The triglyceride issue revisited. Findings from the Helsinki Heart Study. Arch Intern Med 1994, 154(23):2714-2720.
12. Méthot J., Houle J., Poirier P. Obesity: how to define central adiposity?. Expert Rev Cardiovasc Ther 2010, 8(5):639-644.
13. Gabriely I., Ma X.H., Yang X.M., et al. Removal of visceral fat prevents insulin resistance and glucose intolerance of aging: an adipokine-mediated process?. Diabetes 2002, 51(10):2951-2958.
14. Cannon C.P. Cardiovascular disease and modifiable cardiometabolic risk factors. Clin Cornerstone 2007, 8(3):11-28.
15. Willett W.C., Manson J.E., Stampfer M.J., et al. Weight, weight change, and coronary heart disease in women. Risk within the 'normal' weight range. JAMA 1995, 273(6):461-465.
16. Kannel W.B. Habitual level of physical activity and risk of coronary heart disease: the Framingham study. Can Med Assoc J 1967, 96(12):811-812.
17. Sesso H.D., Paffenbarger R.S., Lee I.M. Physical activity and coronary heart disease in men: The Harvard Alumni Health Study. Circulation 2000, 102(9):975-980.
18. Parikh R., Mohan V., Joshi S. Should waist circumference be replaced by index of central obesity (ICO) in definition of metabolic syndrome?. Diabetes Metab Res Rev 2012, 28(1):3-5.
19. Oguma Y., Sesso H.D., Paffenbarger R.S., et al. Weight change and risk of developing type 2 diabetes. Obes Res 2005, 13(5):945-951.
20. Colditz G.A., Willett W.C., Rotnitzky A., et al. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995, 122(7):481-486.
21. Lewis G.F., Carpentier A., Adeli K., et al. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 2002, 23(2):201-229.
22. Pieske B., Wachter R. Impact of diabetes and hypertension on the heart. Curr Opin Cardiol 2008, 23(4):340-349.
23. Aneja A., Tang W.H., Bansilal S., et al. Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options. Am J Med 2008, 121(9):748-757.
24. An D., Rodrigues B. Role of changes in cardiac metabolism in development of diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol 2006, 291(4):H1489-H1506.
25. Fox C.S., Coady S., Sorlie P.D., et al. Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation 2007, 115(12):1544-1550.
26. Lopaschuk G.D., Belke D.D., Gamble J., et al. Regulation of fatty acid oxidation in the mammalian heart in health and disease. Biochim Biophys Acta 1994, 1213(3):263-276.
27. Carley A.N., Severson D.L. Fatty acid metabolism is enhanced in type 2 diabetic hearts. Biochim Biophys Acta 2005, 1734(2):112-126.
28. Longnus S.L., Wambolt R.B., Barr R.L., et al. Regulation of myocardial fatty acid oxidation by substrate supply. Am J Physiol Heart Circ Physiol 2001, 281(4):H1561-H1567.
29. Bharadwaj K.G., Hiyama Y., Hu Y., et al. Chylomicron- and VLDL-derived lipids enter the heart through different pathways: in vivo evidence for receptor- and non-receptor-mediated fatty acid uptake. J Biol Chem 2010, 285(49):37976-37986.
30. Hussain M.M., Kancha R.K., Zhou Z., et al. Chylomicron assembly and catabolism: role of apolipoproteins and receptors. Biochim Biophys Acta 1996, 1300(3):151-170.
31. Nakajima K., Nakano T., Tokita Y., et al. Postprandial lipoprotein metabolism: VLDL vs chylomicrons. Clin Chim Acta 2011, 412(15-16):1306-1318.
32. Havel R.J. Transport and metabolism of chylomicra. Am J Clin Nutr 1958, 6(6):662-668.
33. Skipski V.P., Barclay M., Barclay R.K., et al. Lipid composition of human serum lipoproteins. Biochem J 1967, 104(2):340-352.
34. Heath R.B., Karpe F., Milne R.W., et al. Selective partitioning of dietary fatty acids into the VLDL TG pool in the early postprandial period. J Lipid Res 2003, 44(11):2065-2072.
35. Augustus A., Yagyu H., Haemmerle G., et al. Cardiac-specific knock-out of lipoprotein lipase alters plasma lipoprotein triglyceride metabolism and cardiac gene expression. J Biol Chem 2004, 279(24):25050-25057.
36. Pillutla P., Hwang Y.C., Augustus A., et al. Perfusion of hearts with triglyceride-rich particles reproduces the metabolic abnormalities in lipotoxic cardiomyopathy. Am J Physiol Endocrinol Metab 2005, 288(6):E1229-E1235.
37. Preiss-Landl K., Zimmermann R., Hammerle G., et al. Lipoprotein lipase: the regulation of tissue specific expression and its role in lipid and energy metabolism. Curr Opin Lipidol 2002, 13(5):471-481.
38. Davies B.S., Beigneux A.P., Barnes R.H., et al. GPIHBP1 is responsible for the entry of lipoprotein lipase into capillaries. Cell Metab 2010, 12(1):42-52.
39. Beigneux A.P., Davies B.S., Tat S., et al. Assessing the role of the glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein 1 (GPIHBP1) three-finger domain in binding lipoprotein lipase. J Biol Chem 2011, 286(22):19735-19743.
40. Franssen R., Young S.G., Peelman F., et al. Chylomicronemia with low postheparin lipoprotein lipase levels in the setting of GPIHBP1 defects. Circ Cardiovasc Genet 2010, 3(2):169-178.
41. Yagyu H., Chen G., Yokoyama M., et al. Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy. J Clin Invest 2003, 111(3):419-426.
42. Yagyu H., Lutz E.P., Kako Y., et al. Very low density lipoprotein (VLDL) receptor-deficient mice have reduced lipoprotein lipase activity. Possible causes of hypertriglyceridemia and reduced body mass with VLDL receptor deficiency. J Biol Chem 2002, 277(12):10037-10043.
43. Obunike J.C., Lutz E.P., Li Z., et al. Transcytosis of lipoprotein lipase across cultured endothelial cells requires both heparan sulfate proteoglycans and the very low density lipoprotein receptor. J Biol Chem 2001, 276(12):8934-8941.
44. Goudriaan J.R., Espirito Santo S.M., Voshol P.J., et al. The VLDL receptor plays a major role in chylomicron metabolism by enhancing LPL-mediated triglyceride hydrolysis. J Lipid Res 2004, 45(8):1475-1481.
45. Ibrahimi A., Abumrad N.A. Role of CD36 in membrane transport of long-chain fatty acids. Curr Opin Clin Nutr Metab Care 2002, 5(2):139-145.
46. Brinkmann J.F., Abumrad N.A., Ibrahimi A., et al. New insights into long-chain fatty acid uptake by heart muscle: a crucial role for fatty acid translocase/CD36. Biochem J 2002, 367(Pt 3):561-570.
47. Luiken J.J., Bonen A., Glatz J.F. Cellular fatty acid uptake is acutely regulated by membrane-associated fatty acid-binding proteins. Prostaglandins Leukot Essent Fatty Acids 2002, 67(2-3):73-78.
48. Gimeno R.E., Ortegon A.M., Patel S., et al. Characterization of a heart-specific fatty acid transport protein. J Biol Chem 2003, 278(18):16039-16044.
49. Glatz J.F., Luiken J.J., Bonen A. Involvement of membrane-associated proteins in the acute regulation of cellular fatty acid uptake. J Mol Neurosci 2001, 16(2-3):123-132. [discussion: 151-7].
50. Luiken J.J., Koonen D.P., Willems J., et al. Insulin stimulates long-chain fatty acid utilization by rat cardiac myocytes through cellular redistribution of FAT/CD36. Diabetes 2002, 51(10):3113-3119.
51. Chiu H.C., Kovacs A., Blanton R.M., et al. Transgenic expression of fatty acid transport protein 1 in the heart causes lipotoxic cardiomyopathy. Circ Res 2005, 96(2):225-233.
52. Mashek D.G., Coleman R.A. Cellular fatty acid uptake: the contribution of metabolism. Curr Opin Lipidol 2006, 17(3):274-278.
53. Chess D.J., Stanley W.C. Role of diet and fuel overabundance in the development and progression of heart failure. Cardiovasc Res 2008, 79(2):269-278.
54. Liu Q., Docherty J.C., Rendell J.C., et al. High levels of fatty acids delay the recovery of intracellular pH and cardiac efficiency in post-ischemic hearts by inhibiting glucose oxidation. J Am Coll Cardiol 2002, 39(4):718-725.
55. Buchanan J., Mazumder P.K., Hu P., et al. Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology 2005, 146(12):5341-5349.
56. Boudina S., Sena S., Theobald H., et al. Mitochondrial energetics in the heart in obesity-related diabetes: direct evidence for increased uncoupled respiration and activation of uncoupling proteins. Diabetes 2007, 56(10):2457-2466.
57. Huss J.M., Kelly D.P. Nuclear receptor signaling and cardiac energetics. Circ Res 2004, 95(6):568-578.
58. Brindley D.N. Neuroendocrine regulation and obesity. Int J Obes Relat Metab Disord 1992, 16(Suppl 3):S73-S79.
59. McArthur M.D., Graham S.E., Russell J.C., et al. Exaggerated stress-induced release of nonesterified fatty acids in JCR: LA-corpulent rats. Metabolism 1998, 47(11):1383-1390.
60. Ginsberg H.N. Insulin resistance and cardiovascular disease. J Clin Invest 2000, 106(4):453-458.
61. Bays H., Mandarino L., DeFronzo R.A. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 2004, 89(2):463-478.
62. Aguilera C.M., Gil-Campos M., Canete R., et al. Alterations in plasma and tissue lipids associated with obesity and metabolic syndrome. Clin Sci (Lond) 2008, 114(3):183-193.
63. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1997, 46(1):3-10.
64. Martin-Sanz P., Vance J.E., Brindley D.N. Stimulation of apolipoprotein secretion in very-low-density and high-density lipoproteins from cultured rat hepatocytes by dexamethasone. Biochem J 1990, 271(3):575-583.
65. Wang C.N., McLeod R.S., Yao Z., et al. Effects of dexamethasone on the synthesis, degradation, and secretion of apolipoprotein B in cultured rat hepatocytes. Arterioscler Thromb Vasc Biol 1995, 15(9):1481-1491.
66. Park T.S., Yamashita H., Blaner W.S., et al. Lipids in the heart: a source of fuel and a source of toxins. Curr Opin Lipidol 2007, 18(3):277-282.
67. Pulinilkunnil T., Rodrigues B. Cardiac lipoprotein lipase: metabolic basis for diabetic heart disease. Cardiovasc Res 2006, 69(2):329-340.
68. Ouwens D.M., Diamant M., Fodor M., et al. Cardiac contractile dysfunction in insulin-resistant rats fed a high-fat diet is associated with elevated CD36-mediated fatty acid uptake and esterification. Diabetologia 2007, 50(9):1938-1948.
69. Coort S.L., Hasselbaink D.M., Koonen D.P., et al. Enhanced sarcolemmal FAT/CD36 content and triacylglycerol storage in cardiac myocytes from obese Zucker rats. Diabetes 2004, 53(7):1655-1663.
70. Coort S.L., Luiken J.J., van der Vusse G.J., et al. Increased FAT (fatty acid translocase)/CD36-mediated long-chain fatty acid uptake in cardiac myocytes from obese Zucker rats. Biochem Soc Trans 2004, 32(Pt 1):83-85.
71. Koonen D.P., Febbraio M., Bonnet S., et al. CD36 expression contributes to age-induced cardiomyopathy in mice. Circulation 2007, 116(19):2139-2147.
72. Steinbusch L.K., Schwenk R.W., Ouwens D.M., et al. Subcellular trafficking of the substrate transporters GLUT4 and CD36 in cardiomyocytes. Cell Mol Life Sci 2011, 68(15):2525-2538.
73. 14C-labeled substrates in humans. J Clin Invest 1987, 79(2):359-366.
74. Lopaschuk G.D., Ussher J.R., Folmes C.D., et al. Myocardial fatty acid metabolism in health and disease. Physiol Rev 2010, 90(1):207-258.
75. Li L.O., Klett E.L., Coleman R.A. Acyl-CoA synthesis, lipid metabolism and lipotoxicity. Biochim Biophys Acta 2010, 1801(3):246-251.
76. de Jong H., Neal A.C., Coleman R.A., et al. Ontogeny of mRNA expression and activity of long-chain acyl-CoA synthetase (ACSL) isoforms in Mus musculus heart. Biochim Biophys Acta 2007, 1771(1):75-82.
77. McGarry J.D., Brown N.F. The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. Eur J Biochem 1997, 244(1):1-14.
78. Paulson D.J., Ward K.M., Shug A.L. Malonyl CoA inhibition of carnitine palmitoyltransferase in rat heart mitochondria. FEBS Lett 1984, 176(2):381-384.
79. McGarry J.D., Leatherman G.F., Foster D.W. Carnitine palmitoyltransferase I. The site of inhibition of hepatic fatty acid oxidation by malonyl-CoA. J Biol Chem 1978, 253(12):4128-4136.
80. Saddik M., Gamble J., Witters L.A., et al. Acetyl-CoA carboxylase regulation of fatty acid oxidation in the heart. J Biol Chem 1993, 268(34):25836-25845.
81. Broderick T.L., Panagakis G., DiDomenico D., et al. L-carnitine improvement of cardiac function is associated with a stimulation in glucose but not fatty acid metabolism in carnitine-deficient hearts. Cardiovasc Res 1995, 30(5):815-820.
82. Awan M.M., Saggerson E.D. Malonyl-CoA metabolism in cardiac myocytes and its relevance to the control of fatty acid oxidation. Biochem J 1993, 295(Pt 1):61-66.
83. Cuthbert K.D., Dyck J.R. Malonyl-CoA decarboxylase is a major regulator of myocardial fatty acid oxidation. Curr Hypertens Rep 2005, 7(6):407-411.
84. Schulz H. Chapter 5. Oxidation of fatty acids in eukaryotes. New comprehensive biochemistry 2002, vol. 36:127-150. Elsevier.
85. Finck B.N., Kelly D.P. PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J Clin Invest 2006, 116(3):615-622.
86. Madrazo J.A., Kelly D.P. The PPAR trio: regulators of myocardial energy metabolism in health and disease. J Mol Cell Cardiol 2008, 44(6):968-975.
87. Lin J., Handschin C., Spiegelman B.M. Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab 2005, 1(6):361-370.
88. Barger P.M., Kelly D.P. PPAR signaling in the control of cardiac energy metabolism. Trends Cardiovasc Med 2000, 10(6):238-245.
89. Yang Q., Li Y. Roles of PPARs on regulating myocardial energy and lipid homeostasis. J Mol Med (Berl) 2007, 85(7):697-706.
90. Finck B.N., Gropler M.C., Chen Z., et al. Lipin 1 is an inducible amplifier of the hepatic PGC-1alpha/PPARalpha regulatory pathway. Cell Metab 2006, 4(3):199-210.
91. Watanabe K., Fujii H., Takahashi T., et al. Constitutive regulation of cardiac fatty acid metabolism through peroxisome proliferator-activated receptor alpha associated with age-dependent cardiac toxicity. J Biol Chem 2000, 275(29):22293-22299.
92. Campbell F.M., Kozak R., Wagner A., et al. A role for peroxisome proliferator-activated receptor alpha (PPARalpha) in the control of cardiac malonyl-CoA levels: reduced fatty acid oxidation rates and increased glucose oxidation rates in the hearts of mice lacking PPARalpha are associated with higher concentrations of malonyl-CoA and reduced expression of malonyl-CoA decarboxylase. J Biol Chem 2002, 277(6):4098-4103.
93. Leone T.C., Weinheimer C.J., Kelly D.P. A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders. Proc Natl Acad Sci U S A 1999, 96(13):7473-7478.
94. Leone T.C., Lehman J.J., Finck B.N., et al. PGC-1alpha deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis. PLoS Biol 2005, 3(4):e101.
95. Lehman J.J., Boudina S., Banke N.H., et al. The transcriptional coactivator PGC-1alpha is essential for maximal and efficient cardiac mitochondrial fatty acid oxidation and lipid homeostasis. Am J Physiol Heart Circ Physiol 2008, 295(1):H185-H196.
96. Arany Z., He H., Lin J., et al. Transcriptional coactivator PGC-1 alpha controls the energy state and contractile function of cardiac muscle. Cell Metab 2005, 1(4):259-271.
97. Herrero P., Peterson L.R., McGill J.B., et al. Increased myocardial fatty acid metabolism in patients with type 1 diabetes mellitus. J Am Coll Cardiol 2006, 47(3):598-604.
98. Boudina S., Sena S., O'Neill B.T., et al. Reduced mitochondrial oxidative capacity and increased mitochondrial uncoupling impair myocardial energetics in obesity. Circulation 2005, 112(17):2686-2695.
99. Boudina S., Bugger H., Sena S., et al. Contribution of impaired myocardial insulin signaling to mitochondrial dysfunction and oxidative stress in the heart. Circulation 2009, 119(9):1272-1283.
100. Shen X., Zheng S., Metreveli N.S., et al. Protection of cardiac mitochondria by overexpression of MnSOD reduces diabetic cardiomyopathy. Diabetes 2006, 55(3):798-805.
101. Echtay K.S., Roussel D., St-Pierre J., et al. Superoxide activates mitochondrial uncoupling proteins. Nature 2002, 415(6867):96-99.
102. Ye G., Metreveli N.S., Ren J., et al. Metallothionein prevents diabetes-induced deficits in cardiomyocytes by inhibiting reactive oxygen species production. Diabetes 2003, 52(3):777-783.
103. Lopaschuk G.D., Barr R., Thomas P.D., et al. Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme a thiolase. Circ Res 2003, 93(3):e33-e37.
104. Burgmaier M., Sen S., Philip F., et al. Metabolic adaptation follows contractile dysfunction in the heart of obese Zucker rats fed a high-fat "Western" diet. Obesity (Silver Spring) 2010, 18(10):1895-1901.
105. Finck B.N., Lehman J.J., Leone T.C., et al. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest 2002, 109(1):121-130.
106. Hopkins T.A., Sugden M.C., Holness M.J., et al. Control of cardiac pyruvate dehydrogenase activity in peroxisome proliferator-activated receptor-alpha transgenic mice. Am J Physiol Heart Circ Physiol 2003, 285(1):H270-H276.
107. Lehman J.J., Barger P.M., Kovacs A., et al. Peroxisome proliferator-activated receptor gamma coactivator-1 promotes cardiac mitochondrial biogenesis. J Clin Invest 2000, 106(7):847-856.
108. Dyck J.R., Hopkins T.A., Bonnet S., et al. Absence of malonyl coenzyme A decarboxylase in mice increases cardiac glucose oxidation and protects the heart from ischemic injury. Circulation 2006, 114(16):1721-1728.
109. Dyck J.R., Cheng J.F., Stanley W.C., et al. Malonyl coenzyme A decarboxylase inhibition protects the ischemic heart by inhibiting fatty acid oxidation and stimulating glucose oxidation. Circ Res 2004, 94(9):e78-e84.
110. Lopaschuk G.D., Wall S.R., Olley P.M., et al. Etomoxir, a carnitine palmitoyltransferase I inhibitor, protects hearts from fatty acid-induced ischemic injury independent of changes in long chain acylcarnitine. Circ Res 1988, 63(6):1036-1043.
111. Chandler M.P., Chavez P.N., McElfresh T.A., et al. Partial inhibition of fatty acid oxidation increases regional contractile power and efficiency during demand-induced ischemia. Cardiovasc Res 2003, 59(1):143-151.
112. Yang J., Sambandam N., Han X., et al. CD36 deficiency rescues lipotoxic cardiomyopathy. Circ Res 2007, 100(8):1208-1217.
113. Foley J.E. Rationale and application of fatty acid oxidation inhibitors in treatment of diabetes mellitus. Diabetes Care 1992, 15(6):773-784.
114. Larsen T.S., Aasum E. Metabolic (in)flexibility of the diabetic heart. Cardiovasc Drugs Ther 2008, 22(2):91-95.
115. Kennedy E.P. The biological synthesis of phospholipids. Can J Biochem Physiol 1956, 34(2):334-348.
116. Weiss S.B., Kennedy E.P., Kiyasu J.Y. The enzymatic synthesis of triglycerides. J Biol Chem 1960, 235:40-44.
117. Brindley D.N., Kok B.P., Kienesberger P.C., et al. Shedding light on the enigma of myocardial lipotoxicity: the involvement of known and putative regulators of fatty acid storage and mobilization. Am J Physiol Endocrinol Metab 2010, 298(5):E897-E908.
118. Coleman R.A., Lee D.P. Enzymes of triacylglycerol synthesis and their regulation. Prog Lipid Res 2004, 43(2):134-176.
119. Kim J.Y., Park H.S., Kang S.I., et al. Redox regulation of cytosolic glycerol-3-phosphate dehydrogenase: Cys(102) is the target of the redox control and essential for the catalytic activity. Biochim Biophys Acta 2002, 1569(1-3):67-74.
120. Robinson J., Newsholme E.A. Glycerol kinase activities in rat heart and adipose tissue. Biochem J 1967, 104(1):2C-4C.
121. Golovko M.Y., Hovda J.T., Cai Z.J., et al. Tissue-dependent alterations in lipid mass in mice lacking glycerol kinase. Lipids 2005, 40(3):287-293.
122. Takeuchi K., Reue K. Biochemistry, physiology, and genetics of GPAT, AGPAT, and lipin enzymes in triglyceride synthesis. Am J Physiol Endocrinol Metab 2009, 296(6):E1195-E1209.
123. Wendel A.A., Lewin T.M., Coleman R.A. Glycerol-3-phosphate acyltransferases: rate limiting enzymes of triacylglycerol biosynthesis. Biochim Biophys Acta 2009, 1791(6):501-506.
124. Lewin T.M., de Jong H., Schwerbrock N.J., et al. Mice deficient in mitochondrial glycerol-3-phosphate acyltransferase-1 have diminished myocardial triacylglycerol accumulation during lipogenic diet and altered phospholipid fatty acid composition. Biochim Biophys Acta 2008, 1781(6-7):352-358.
125. Lu B., Jiang Y.J., Zhou Y., et al. Cloning and characterization of murine 1-acyl-sn-glycerol 3-phosphate acyltransferases and their regulation by PPARalpha in murine heart. Biochem J 2005, 385(Pt 2):469-477.
126. Reue K., Brindley D.N. Thematic Review Series: glycerolipids. Multiple roles for lipins/phosphatidate phosphatase enzymes in lipid metabolism. J Lipid Res 2008, 49(12):2493-2503.
127. Donkor J., Sariahmetoglu M., Dewald J., et al. Three mammalian lipins act as phosphatidate phosphatases with distinct tissue expression patterns. J Biol Chem 2007, 282(6):3450-3457.
128. 2+-dependent phosphatidate phosphatase enzyme. J Biol Chem 2006, 281(14):9210-9218.
129. Liu G.H., Qu J., Carmack A.E., et al. Lipin proteins form homo- and hetero-oligomers. Biochem J 2010, 432(1):65-76.
130. Han G.S., Carman G.M. Characterization of the human LPIN1-encoded phosphatidate phosphatase isoforms. J Biol Chem 2010, 285(19):14628-14638.
131. Donkor J., Zhang P., Wong S., et al. A conserved serine residue is required for the phosphatidate phosphatase activity but not the transcriptional coactivator functions of lipin-1 and lipin-2. J Biol Chem 2009, 284(43):29968-29978.
132. Harris T.E., Huffman T.A., Chi A., et al. Insulin controls subcellular localization and multisite phosphorylation of the phosphatidic acid phosphatase, lipin 1. J Biol Chem 2007, 282(1):277-286.
133. Peterson T.R., Sengupta S.S., Harris T.E., et al. mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. Cell 2011, 146(3):408-420.
134. Ren H., Federico L., Huang H., et al. A phosphatidic acid binding/nuclear localization motif determines lipin-1 function in lipid metabolism and adipogenesis. Mol Biol Cell 2010, 21(18):3171-3181.
135. Hopewell R., Martin-Sanz P., Martin A., et al. Regulation of the translocation of phosphatidate phosphohydrolase between the cytosol and the endoplasmic reticulum of rat liver. Effects of unsaturated fatty acids, spermine, nucleotides, albumin and chlorpromazine. Biochem J 1985, 232(2):485-491.
136. Martin-Sanz P., Hopewell R., Brindley D.N. Long-chain fatty acids and their acyl-CoA esters cause the translocation of phosphatidate phosphohydrolase from the cytosolic to the microsomal fraction of rat liver. FEBS Lett 1984, 175(2):284-288.
137. Cascales C., Mangiapane E.H., Brindley D.N. Oleic acid promotes the activation and translocation of phosphatidate phosphohydrolase from the cytosol to particulate fractions of isolated rat hepatocytes. Biochem J 1984, 219(3):911-916.
138. Luiken J.J., Arumugam Y., Dyck D.J., et al. Increased rates of fatty acid uptake and plasmalemmal fatty acid transporters in obese Zucker rats. J Biol Chem 2001, 276(44):40567-40573.
139. Liu G.H., Gerace L. Sumoylation regulates nuclear localization of lipin-1alpha in neuronal cells. PLoS One 2009, 4(9):e7031.
140. Peterfy M., Harris T.E., Fujita N., et al. Insulin-stimulated interaction with 14-3-3 promotes cytoplasmic localization of lipin-1 in adipocytes. J Biol Chem 2010, 285(6):3857-3864.
141. Manmontri B., Sariahmetoglu M., Donkor J., et al. Glucocorticoids and cyclic AMP selectively increase hepatic lipin-1 expression, and insulin acts antagonistically. J Lipid Res 2008, 49(5):1056-1067.
142. Zhang P., O'Loughlin L., Brindley D.N., et al. Regulation of lipin-1 gene expression by glucocorticoids during adipogenesis. J Lipid Res 2008, 49(7):1519-1528.
143. Mitra M.S., Schilling J.D., Wang X., et al. Cardiac lipin 1 expression is regulated by the peroxisome proliferator activated receptor gamma coactivator 1alpha/estrogen related receptor axis. J Mol Cell Cardiol 2011, 51(1):120-128.
144. Ryu D., Oh K.J., Jo H.Y., et al. TORC2 regulates hepatic insulin signaling via a mammalian phosphatidic acid phosphatase, LIPIN1. Cell Metab 2009, 9(3):240-251.
145. Ishimoto K., Nakamura H., Tachibana K., et al. Sterol-mediated regulation of human lipin 1 gene expression in hepatoblastoma cells. J Biol Chem 2009, 284(33):22195-22205.
146. Hu M., Wang F., Li X., et al. Regulation of hepatic lipin-1 by ethanol: role of AMP-activated protein kinase/sterol regulatory element-binding protein 1 signaling in mice. Hepatology 2012, 55(2):437-446.
147. Pearen M.A., Myers S.A., Raichur S., et al. The orphan nuclear receptor, NOR-1, a target of beta-adrenergic signaling, regulates gene expression that controls oxidative metabolism in skeletal muscle. Endocrinology 2008, 149(6):2853-2865.
148. Kim D.K., Kim J.R., Koh M., et al. Estrogen-related receptor gamma (ERRgamma) is a novel transcriptional regulator of phosphatidic acid phosphatase, LIPIN1, and inhibits hepatic insulin signaling. J Biol Chem 2011, 286(44):38035-38042.
149. Burgdorf C., Hansel L., Heidbreder M., et al. Suppression of cardiac phosphatidate phosphohydrolase 1 activity and lipin mRNA expression in Zucker diabetic fatty rats and humans with type 2 diabetes mellitus. Biochem Biophys Res Commun 2009, 390(1):165-170.
150. Kok B.P., Kienesberger P.C., Dyck J.R., et al. Relationship of glucose and oleate metabolism to cardiac function in lipin-1 deficient (fld) mice. J Lipid Res 2012, 53(1):105-118. [Epub 2011 Nov 5].
151. Zammit V.A., Buckett L.K., Turnbull A.V., et al. Diacylglycerol acyltransferases: potential roles as pharmacological targets. Pharmacol Ther 2008, 118(3):295-302.
152. Yen C.L., Stone S.J., Koliwad S., et al. Thematic review series: glycerolipids. DGAT enzymes and triacylglycerol biosynthesis. J Lipid Res 2008, 49(11):2283-2301.
153. Stone S.J., Levin M.C., Farese R.V. Membrane topology and identification of key functional amino acid residues of murine acyl-CoA:diacylglycerol acyltransferase-2. J Biol Chem 2006, 281(52):40273-40282.
154. Stone S.J., Levin M.C., Zhou P., et al. The endoplasmic reticulum enzyme DGAT2 is found in mitochondria-associated membranes and has a mitochondrial targeting signal that promotes its association with mitochondria. J Biol Chem 2009, 284(8):5352-5361.
155. McFie P.J., Banman S.L., Kary S., et al. Murine diacylglycerol acyltransferase-2 (DGAT2) can catalyze triacylglycerol synthesis and promote lipid droplet formation independent of its localization to the endoplasmic reticulum. J Biol Chem 2011, 286(32):28235-28246.
156. Harris C.A., Haas J.T., Streeper R.S., et al. DGAT enzymes are required for triacylglycerol synthesis and lipid droplets in adipocytes. J Lipid Res 2011, 52(4):657-667.
157. Yen C.L., Monetti M., Burri B.J., et al. The triacylglycerol synthesis enzyme DGAT1 also catalyzes the synthesis of diacylglycerols, waxes, and retinyl esters. J Lipid Res 2005, 46(7):1502-1511.
158. Shih M.Y., Kane M.A., Zhou P., et al. Retinol esterification by DGAT1 is essential for retinoid homeostasis in murine skin. J Biol Chem 2009, 284(7):4292-4299.
159. Stone S.J., Myers H.M., Watkins S.M., et al. Lipopenia and skin barrier abnormalities in DGAT2-deficient mice. J Biol Chem 2004, 279(12):11767-11776.
160. Liu L., Shi X., Choi C.S., et al. Paradoxical coupling of triglyceride synthesis and fatty acid oxidation in skeletal muscle overexpressing DGAT1. Diabetes 2009, 58(11):2516-2524.
161. Liu L., Shi X., Bharadwaj K.G., et al. DGAT1 expression increases heart triglyceride content but ameliorates lipotoxicity. J Biol Chem 2009, 284(52):36312-36323.
162. Levin M.C., Monetti M., Watt M.J., et al. Increased lipid accumulation and insulin resistance in transgenic mice expressing DGAT2 in glycolytic (type II) muscle. Am J Physiol Endocrinol Metab 2007, 293(6):E1772-E1781.
163. Monetti M., Levin M.C., Watt M.J., et al. Dissociation of hepatic steatosis and insulin resistance in mice overexpressing DGAT in the liver. Cell Metab 2007, 6(1):69-78.
164. Liu L., Zhang Y., Chen N., et al. Upregulation of myocellular DGAT1 augments triglyceride synthesis in skeletal muscle and protects against fat-induced insulin resistance. J Clin Invest 2007, 117(6):1679-1689.
165. Glenn D.J., Wang F., Nishimoto M., et al. A murine model of isolated cardiac steatosis leads to cardiomyopathy. Hypertension 2011, 57(2):216-222.
166. Boudina S., Abel E.D. Mitochondrial uncoupling: a key contributor to reduced cardiac efficiency in diabetes. Physiology (Bethesda) 2006, 21:250-258.
167. Aasum E., Cooper M., Severson D.L., et al. Effect of BM 17.0744, a PPARalpha ligand, on the metabolism of perfused hearts from control and diabetic mice. Can J Physiol Pharmacol 2005, 83(2):183-190.
168. Szczepaniak L.S., Victor R.G., Orci L., et al. Forgotten but not gone: the rediscovery of fatty heart, the most common unrecognized disease in America. Circ Res 2007, 101(8):759-767.
169. Brookheart R.T., Michel C.I., Schaffer J.E. As a matter of fat. Cell Metab 2009, 10(1):9-12.
170. Harmancey R., Wilson C.R., Taegtmeyer H. Adaptation and maladaptation of the heart in obesity. Hypertension 2008, 52(2):181-187.
171. Luiken J.J. Sarcolemmal fatty acid uptake vs. mitochondrial beta-oxidation as target to regress cardiac insulin resistance. Appl Physiol Nutr Metab 2009, 34(3):473-480.
172. Chiu H.C., Kovacs A., Ford D.A., et al. A novel mouse model of lipotoxic cardiomyopathy. J Clin Invest 2001, 107(7):813-822.
173. Schaffer J.E. Lipotoxicity: when tissues overeat. Curr Opin Lipidol 2003, 14(3):281-287.
174. Kusminski C.M., Shetty S., Orci L., et al. Diabetes and apoptosis: lipotoxicity. Apoptosis 2009, 14(12):1484-1495.
175. Wende A.R., Abel E.D. Lipotoxicity in the heart. Biochim Biophys Acta 2010, 1801(3):311-319. [Epub 2009 Oct 8].
176. Sparagna G.C., Hickson-Bick D.L., Buja L.M., et al. A metabolic role for mitochondria in palmitate-induced cardiac myocyte apoptosis. Am J Physiol Heart Circ Physiol 2000, 279(5):H2124-H2132.
177. Coll T., Eyre E., Rodriguez-Calvo R., et al. Oleate reverses palmitate-induced insulin resistance and inflammation in skeletal muscle cells. J Biol Chem 2008, 283(17):11107-11116.
178. Chavez J.A., Summers S.A. Characterizing the effects of saturated fatty acids on insulin signaling and ceramide and diacylglycerol accumulation in 3T3-L1 adipocytes and C2C12 myotubes. Arch Biochem Biophys 2003, 419(2):101-109.
179. Powell D.J., Turban S., Gray A., et al. Intracellular ceramide synthesis and protein kinase Czeta activation play an essential role in palmitate-induced insulin resistance in rat L6 skeletal muscle cells. Biochem J 2004, 382(Pt 2):619-629.
180. Russell L.K., Finck B.N., Kelly D.P. Mouse models of mitochondrial dysfunction and heart failure. J Mol Cell Cardiol 2005, 38(1):81-91.
181. Basu R., Oudit G.Y., Wang X., et al. Type 1 diabetic cardiomyopathy in the Akita (Ins2WT/C96Y) mouse model is characterized by lipotoxicity and diastolic dysfunction with preserved systolic function. Am J Physiol Heart Circ Physiol 2009, 297(6):H2096-H2108.
182. Zhang L., Ussher J.R., Oka T., et al. Cardiac diacylglycerol accumulation in high fat-fed mice is associated with impaired insulin-stimulated glucose oxidation. Cardiovasc Res 2011, 89(1):148-156.
183. Park T.S., Hu Y., Noh H.L., et al. Ceramide is a cardiotoxin in lipotoxic cardiomyopathy. J Lipid Res 2008, 49(10):2101-2112.
184. Drosatos K., Bharadwaj K.G., Lymperopoulos A., et al. Cardiomyocyte lipids impair beta-adrenergic receptor function via PKC activation. Am J Physiol Endocrinol Metab 2011, 300(3):E489-E499.
185. Stanley W.C., Recchia F.A., Lopaschuk G.D. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 2005, 85(3):1093-1129.
186. Saddik M., Lopaschuk G.D. Myocardial triglyceride turnover and contribution to energy substrate utilization in isolated working rat hearts. J Biol Chem 1991, 266(13):8162-8170.
187. Banke N.H., Wende A.R., Leone T.C., et al. Preferential oxidation of triacylglyceride-derived fatty acids in heart is augmented by the nuclear receptor PPARalpha. Circ Res 2010, 107(2):233-241.
188. Swanton E.M., Saggerson E.D. Effects of adrenaline on triacylglycerol synthesis and turnover in ventricular myocytes from adult rats. Biochem J 1997, 328(Pt 3):913-922.
189. Zechner R., Zimmermann R., Eichmann T.O., et al. FAT SIGNALS-lipases and lipolysis in lipid metabolism and signaling. Cell Metab 2012, 15(3):279-291.
190. Haemmerle G., Lass A., Zimmermann R., et al. Defective lipolysis and altered energy metabolism in mice lacking adipose triglyceride lipase. Science 2006, 312(5774):734-737.
191. Holm C., Kirchgessner T.G., Svenson K.L., et al. Hormone-sensitive lipase: sequence, expression, and chromosomal localization to 19 cent-q13.3. Science 1988, 241(4872):1503-1506.
192. Dolinsky V.W., Sipione S., Lehner R., et al. The cloning and expression of a murine triacylglycerol hydrolase cDNA and the structure of its corresponding gene. Biochim Biophys Acta 2001, 1532(3):162-172.
193. Karlsson M., Contreras J.A., Hellman U., et al. cDNA cloning, tissue distribution, and identification of the catalytic triad of monoglyceride lipase. Evolutionary relationship to esterases, lysophospholipases, and haloperoxidases. J Biol Chem 1997, 272(43):27218-27223.
194. Lass A., Zimmermann R., Haemmerle G., et al. Adipose triglyceride lipase-mediated lipolysis of cellular fat stores is activated by CGI-58 and defective in Chanarin-Dorfman syndrome. Cell Metab 2006, 3(5):309-319.
195. Schoiswohl G., Schweiger M., Schreiber R., et al. Adipose triglyceride lipase plays a key role in the supply of the working muscle with fatty acids. J Lipid Res 2010, 51(3):490-499.
196. Haemmerle G., Moustafa T., Woelkart G., et al. ATGL-mediated fat catabolism regulates cardiac mitochondrial function via PPAR-alpha and PGC-1. Nat Med 2011, 17(9):1076-1085.
197. Duncan J.G., Bharadwaj K.G., Fong J.L., et al. Rescue of cardiomyopathy in peroxisome proliferator-activated receptor-alpha transgenic mice by deletion of lipoprotein lipase identifies sources of cardiac lipids and peroxisome proliferator-activated receptor-alpha activators. Circulation 2010, 121(3):426-435.
198. Schweiger M., Lass A., Zimmermann R., et al. Neutral lipid storage disease: genetic disorders caused by mutations in adipose triglyceride lipase/PNPLA2 or CGI-58/ABHD5. Am J Physiol Endocrinol Metab 2009, 297(2):E289-E296.
199. Hirano K., Ikeda Y., Zaima N., et al. Triglyceride deposit cardiomyovasculopathy. N Engl J Med 2008, 359(22):2396-2398.
200. Haemmerle G., Zimmermann R., Hayn M., et al. Hormone-sensitive lipase deficiency in mice causes diglyceride accumulation in adipose tissue, muscle, and testis. J Biol Chem 2002, 277(7):4806-4815.
201. Park S.Y., Kim H.J., Wang S., et al. Hormone-sensitive lipase knockout mice have increased hepatic insulin sensitivity and are protected from short-term diet-induced insulin resistance in skeletal muscle and heart. Am J Physiol Endocrinol Metab 2005, 289(1):E30-E39.
202. Zimmermann R., Haemmerle G., Wagner E.M., et al. Decreased fatty acid esterification compensates for the reduced lipolytic activity in hormone-sensitive lipase-deficient white adipose tissue. J Lipid Res 2003, 44(11):2089-2099.
203. Suzuki J., Shen W.J., Nelson B.D., et al. Absence of cardiac lipid accumulation in transgenic mice with heart-specific HSL overexpression. Am J Physiol Endocrinol Metab 2001, 281(4):E857-E866.
204. Ueno M., Suzuki J., Zenimaru Y., et al. Cardiac overexpression of hormone-sensitive lipase inhibits myocardial steatosis and fibrosis in streptozotocin diabetic mice. Am J Physiol Endocrinol Metab 2008, 294(6):E1109-E1118.
205. Kienesberger P.C., Pulinilkunnil T., Sung M.M., et al. Myocardial ATGL overexpression decreases the reliance on fatty acid oxidation and protects against pressure overload-induced cardiac dysfunction. Mol Cell Biol 2012, 32(4):740-750.
206. Taschler U., Radner F.P., Heier C., et al. Monoglyceride lipase deficiency in mice impairs lipolysis and attenuates diet-induced insulin resistance. J Biol Chem 2011, 286(20):17467-17477.
207. Gilham D., Ho S., Rasouli M., et al. Inhibitors of hepatic microsomal triacylglycerol hydrolase decrease very low density lipoprotein secretion. FASEB J 2003, 17(12):1685-1687.
208. Wei E., Alam M., Sun F., et al. Apolipoprotein B and triacylglycerol secretion in human triacylglycerol hydrolase transgenic mice. J Lipid Res 2007, 48(12):2597-2606.
209. Bartels E.D., Nielsen J.M., Hellgren L.I., et al. Cardiac expression of microsomal triglyceride transfer protein is increased in obesity and serves to attenuate cardiac triglyceride accumulation. PLoS One 2009, 4(4):e5300.
210. Boren J., Veniant M.M., Young S.G. Apo B100-containing lipoproteins are secreted by the heart. J Clin Invest 1998, 101(6):1197-1202.
211. Stephens T.W., Higgins A.J., Cook G.A., et al. Two mechanisms produce tissue-specific inhibition of fatty acid oxidation by oxfenicine. Biochem J 1985, 227(2):651-660.
212. Fragasso G., Piatti Md P.M., Monti L., et al. Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Am Heart J 2003, 146(5):E18.
213. Vitale C., Wajngaten M., Sposato B., et al. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur Heart J 2004, 25(20):1814-1821.
214. Kantor P.F., Lucien A., Kozak R., et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2000, 86(5):580-588.
215. Sabbah H.N., Chandler M.P., Mishima T., et al. Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure. J Card Fail 2002, 8(6):416-422.
216. Chaitman B.R. Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions. Circulation 2006, 113(20):2462-2472.
217. Cheng J.F., Huang Y., Penuliar R., et al. Discovery of potent and orally available malonyl-CoA decarboxylase inhibitors as cardioprotective agents. J Med Chem 2006, 49(14):4055-4058.
218. Elam M.B., Hunninghake D.B., Davis K.B., et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. Arterial Disease Multiple Intervention Trial. JAMA 2000, 284(10):1263-1270.
219. Taylor A.J., Villines T.C., Stanek E.J., et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009, 361(22):2113-2122.
220. Garcia-Calvo M., Lisnock J., Bull H.G., et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci U S A 2005, 102(23):8132-8137.
221. Dunn C.J., Peters D.H. Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 1995, 49(5):721-749.
222. Bolen S., Feldman L., Vassy J., et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007, 147(6):386-399.
223. Abourbih S., Filion K.B., Joseph L., et al. Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review. Am J Med 2009, 122(10):962. e1-8.
224. Barter P.J., Rye K.A. Cardioprotective properties of fibrates: which fibrate, which patients, what mechanism?. Circulation 2006, 113(12):1553-1555.
225. Law M.R., Wald N.J., Rudnicka A.R. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003, 326(7404):1423.
226. Hebert P.R., Gaziano J.M., Chan K.S., et al. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 1997, 278(4):313-321.
227. Zinn A., Felson S., Fisher E., et al. Reassessing the cardiovascular risks and benefits of thiazolidinediones. Clin Cardiol 2008, 31(9):397-403.
228. Khanderia U., Pop-Busui R., Eagle K.A. Thiazolidinediones in type 2 diabetes: a cardiology perspective. Ann Pharmacother 2008, 42(10):1466-1474.
229. O'Meara E., McMurray J.J. Myocardial metabolic manipulation: a new therapeutic approach in heart failure?. Heart 2005, 91(2):131-132.
230. Taegtmeyer H. Cardiac metabolism as a target for the treatment of heart failure. Circulation 2004, 110(8):894-896.
231. Yan J., Young M.E., Cui L., et al. Increased glucose uptake and oxidation in mouse hearts prevent high fatty acid oxidation but cause cardiac dysfunction in diet-induced obesity. Circulation 2009, 119(21):2818-2828.
232. Augustus A.S., Buchanan J., Park T.S., et al. Loss of lipoprotein lipase-derived fatty acids leads to increased cardiac glucose metabolism and heart dysfunction. J Biol Chem 2006, 281(13):8716-8723.
233. Fazio S. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy. Clin Ther 2008, 30(2):294-306.
234. Brown B.G., Zhao X.Q., Chait A., et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001, 345(22):1583-1592.
235. Graham D.J., Staffa J.A., Shatin D., et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004, 292(21):2585-2590.